Khaliullin, F.A.,
Klen, E.E.,
Nikitina, I.L.,
Pavlov, V.N.,
Rozit, G.A.,
Gaisina, G.G.,
Samorodov, A.V. (2023) . An in vivo study of the
antidepressant activity revealed the promising compound 1-(1,1-dioxidothietan-3-yl)-4
Klen, E.E.,
Nikitina, I.L.,
Khaliullin, F.A.,
Shepilova, S.O.,
Nikitina, E.A.,
Gaisina, G.G.,
Samorodov, A.V.,
Pavlov, V.N. (2024) bioavailability. The compounds exhibited varying degrees of
antidepressant activity after a single intraperitoneal
Khaliullin, F. A.,
Klen, E. E.,
Nikitina, I. L.,
Pavlov, V. N.,
Rozit, G. A.,
Gaisina, G. G.,
Samorodov, A. V. (2023) . An in vivo
study of the
antidepressant activity revealed the promising compound 1-(1,1-dioxidothietan-3-yl)-4
-crown-6 ether in toluene. In vitro anticoagulant and antiplatelet
activity of the adduct was studied
KHALIULLIN, F.A.,
KLEN, E.E.,
PAVLOV, V.N.,
SAMORODOV, A.V.,
SHEPILOVA, S.O.,
MAKAROVA, N.N.,
NURLANOVA, S.N.,
ABZALILOV, T.N. (2022)
studies of the antiplatelet, anticoagulant, and antioxidant
activity revealed promising compounds
Qian, J.,
Zhuang, F.,
Chen, Y.,
Fan, X.,
Wang, J.,
Wang, Z.,
Wang, Y.,
Xu, M.,
Samorodov, A.V.,
Pavlov, V.N.,
Liang, G. (2022) under high glucose condition, which was mediated by p38MAPK
activation. MD2 knockout or pharmacological
Yang, L.,
Luo, W.,
Zhang, Q,
Hong, S.,
Wang, Y.,
Samorodov, A.V.,
Chattipakorn, N.,
Pavlov, V.N.,
Liang, G. (2021) compounds were screened for their anti-inflammatory
activity in LPS-stimulated macrophages. PCR array, SPR